Popular on PrZen
- LS2 Partners with Angels Of Dirt's "Next Chapter Racer" Series Celebrating Women and Girls in Motorsports - 640
- Meta Partnership Expanding as Omni One Orders Surge 3X -New Consumer Bundles, Defense Opportunities & AI Robotics: Virtuix Holdings: N A S D A Q: VTIX - 611
- Alan Hamilton of Shiver Hamilton Campbell Inducted as a Fellow of the American College of Trial Lawyers - 606
- OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki - 600
- Club Wyndham Research Identifies the "Holiday Rewind Effect": 93% of Parents Recreate Their Own Childhood Holidays for Their Kids - 579
- The 4th Annual Newark Summit for Economic Development, Placemaking & Innovation Returns on December 8th - 578
- Constantine "Costa" Kapothanasis II Acquires The Lubri-Loy Company, Carrying a 77-Year-Old American Lubricant Brand Into Its Next Era - 568
- Citizens for West Virginia Election Integrity Urges "FOR" on Amendment 1 - 565
- "The Tree of Cinema" Installation Brought Film History and Its Audiences Together at TIFF 2026 - 541
- Creole101 Launches Multilingual Dictionary App with 50,000+ Entries, Vocabulary Games and Haitian Cultural Resources - 528
Similar on PrZen
- Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
- Qscription Technologies Welcomes Joanna Krause, MD, MRMD to Its Clinical Advisory Board
- New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
- OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
- New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
- New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc
- FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
- Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
- Canadian Woman Plants 1,667 Love Stories in a Field of Peonies That Could Bloom for 100 Years
- New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX)
Biophysical Therapeutics brings longevity science to skincare with its new IF1 brand
PrZen/33624458
From equations and experiments in the laboratory to exclusive skincare for skin longevity
WILMINGTON, Del. - PrZen -- Biophysical Therapeutics, a Delaware company, announces the launch of its consumer longevity brand called IF1.
It is currently accepting pre-orders for its first product, an anti-aging skin moisturizer available at www.IF1.skin. Only 500 units are available in the initial production run, retailing at $120 apiece.
This moisturizer is distinctive in incorporating leading-edge longevity science, and is further distinct, since the profit from its sales will feed back to fund the company's drug programs, which include drugs against cancer, age-related diseases (such as Alzheimer's disease), and aging itself.
The company was founded in 2022 by Dr. Michael Forrest, a Cambridge University biochemistry graduate with a Ph.D. in computer science, and is advised by Professor George Church of Harvard Medical School. Its specialty is computational biology and especially biophysical modeling, which is mathematical modeling of the physics and chemistry of a biological system, and the company is named after this approach. Unusually for a computational biology company, it has actually delivered new experimentally-validated drugs working as predicted in vivo, protected by granted patents.
The science behind the company's new anti-aging skin moisturizer is its conclusion regarding why different mammal species can have such different lifespans, for example, a mouse maximally lives 4 years whereas a bowhead whale can live centuries longer. This conclusion is complex but it distills to simplicity - species with more IF1 protein live longer. Indeed, the company has shown that increasing IF1 protein in mice reduces aging as measured by an aging biomarker.
People already buy anti-aging skincare. Indeed, it is already a $70B market and growing. This bodes well for this new brand that leverages differentiated anti-aging science from leading anti-aging scientists, which will in turn fund them to advance science and medicine. Economists calculate that the economic benefit of slower aging, to the USA alone, is $38T per year of increased life expectancy.
Dr. Forrest says: "Our IF1 brand brings leading-edge anti-aging science to skincare. This is just part of our mission to save, improve, and extend lives at mass scale."
The IF1 anti-aging skin moisturizer is available for pre-order now exclusively at www.IF1.skin.
About Biophysical Therapeutics
Biophysical Therapeutics is a Delaware-based biotechnology company that uses computational biology, especially biophysical modeling, to discover new fundamental biology and design new drugs. Its primary targets are cancer, the diseases of aging (e.g., Alzheimer's disease), and aging itself. The company has a pipeline of experimentally-validated new drugs and a portfolio of granted patents. It owns a longevity skincare brand called IF1, which is available at www.IF1.skin.
It is currently accepting pre-orders for its first product, an anti-aging skin moisturizer available at www.IF1.skin. Only 500 units are available in the initial production run, retailing at $120 apiece.
This moisturizer is distinctive in incorporating leading-edge longevity science, and is further distinct, since the profit from its sales will feed back to fund the company's drug programs, which include drugs against cancer, age-related diseases (such as Alzheimer's disease), and aging itself.
The company was founded in 2022 by Dr. Michael Forrest, a Cambridge University biochemistry graduate with a Ph.D. in computer science, and is advised by Professor George Church of Harvard Medical School. Its specialty is computational biology and especially biophysical modeling, which is mathematical modeling of the physics and chemistry of a biological system, and the company is named after this approach. Unusually for a computational biology company, it has actually delivered new experimentally-validated drugs working as predicted in vivo, protected by granted patents.
The science behind the company's new anti-aging skin moisturizer is its conclusion regarding why different mammal species can have such different lifespans, for example, a mouse maximally lives 4 years whereas a bowhead whale can live centuries longer. This conclusion is complex but it distills to simplicity - species with more IF1 protein live longer. Indeed, the company has shown that increasing IF1 protein in mice reduces aging as measured by an aging biomarker.
People already buy anti-aging skincare. Indeed, it is already a $70B market and growing. This bodes well for this new brand that leverages differentiated anti-aging science from leading anti-aging scientists, which will in turn fund them to advance science and medicine. Economists calculate that the economic benefit of slower aging, to the USA alone, is $38T per year of increased life expectancy.
Dr. Forrest says: "Our IF1 brand brings leading-edge anti-aging science to skincare. This is just part of our mission to save, improve, and extend lives at mass scale."
The IF1 anti-aging skin moisturizer is available for pre-order now exclusively at www.IF1.skin.
About Biophysical Therapeutics
Biophysical Therapeutics is a Delaware-based biotechnology company that uses computational biology, especially biophysical modeling, to discover new fundamental biology and design new drugs. Its primary targets are cancer, the diseases of aging (e.g., Alzheimer's disease), and aging itself. The company has a pipeline of experimentally-validated new drugs and a portfolio of granted patents. It owns a longevity skincare brand called IF1, which is available at www.IF1.skin.
Source: Biophysical Therapeutics
0 Comments
Latest on PrZen
- Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
- The World's No.1 Superstar® Brings Christmas Back in Grand Style with Music, Cinematic Glamour, and Luxury Fashion
- New Six-Figure Media Agreement Builds Powerful Momentum, Expanding Government Contracts, FBI Access and Growing AI Recognition: Cyabra (NAS DAQ: CYAB)
- Christmas Beats Summer in Paris: Travel Photoshoots Peak on Dec. 30
- Qscription Technologies Welcomes Joanna Krause, MD, MRMD to Its Clinical Advisory Board
- Jamie Foxx's SKVLK Fest Sets the Record Straight on Stabbing Reports Following Star-Studded Celebration
- Andrew Balzano Releases One of My Life's Passions: Classics and Mysteries, a Fan's Guide to Great Mysteries Worth Rewatching
- The 4th Annual Newark Summit for Economic Development, Placemaking & Innovation Returns on December 8th
- Romanian Software Company ASSIST Software Ranks Second Nationally Among Large Enterprises in Its Category
- HIRO Ostomy Belt Launch by Richard O'Hamill
- New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
- Technical Brief Examines Enterprise Integration Challenges as AI Agent Platforms Expand
- OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
- Brian G. Miller Co., LLC Receives Tier 1 Ranking in the 2027 Edition of Best Law Firms®
- The Villari Firm, PLLC Named to the 2027 Edition of Best Law Firms
- Bacchus Wine & Spirits and Michelin Guide–Recommended Ethel's Fancy to Host Exclusive LOUIS XIII Limited Edition Diwali Decanter Celebration
- Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs
- ZenaTech (NAS DAQ: ZENA) $1 Million in New Utility Contracts- Potential $2.5 Million Follow-On Opportunity Puts Its Drone Business in the Spotlight!
- New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
- Genuine Hospitality, LLC Selected to Operate Holiday Inn Express & Suites Jacksonville – Town Center
